{"status":"success","data":{"title":"Cystitis and Pyelonephritis in Women","slug":"cystitis-pregnant","tags":["Nitrofurantoin","sulfamethoxazole","fosfomycin","pivmecillinam","ofloxacin","ciprofloxacin","levofloxacin","amoxicillin-clavulanate","cefdinir","cefaclor","cefpodoxime-proxetil","Trimethoprim-sulfamethoxazole"],"collection":["Infectious Disease","Genitourinary"],"content":"<h1 id=\"cystitis-and-pyelonephritis-in-women\">Cystitis and Pyelonephritis in Women</h1>\n<p><strong>2010 IDSA and ESMID guidelines on antibiotic selection</strong></p>\n<p>Target population = Acute, uncomplicated cystitis and pyelonephritis in women </p>\n<ul>\n<li>Premenopausal, non-pregnant women without known urological abnormalities or co-morbidities (i.e. DM)</li>\n</ul>\n<h2 id=\"acute-uncomplicated-cystitis\">Acute uncomplicated cystitis</h2>\n<p><strong><span class=\"drug\">Nitrofurantoin</span></strong> (100 mg PO BID x 5 days)\n<strong><span class=\"drug\">Trimethoprim</span>-sulfamethoxazole</strong> (1 DS tab PO BID x 3 days)</p>\n<ol>\n<li>Rising resistance rates </li>\n<li>Only give if local antibiogram shows &lt; 20% resistance</li>\n</ol>\n<p><strong><span class=\"drug\">Fosfomycin</span></strong> (3 gm PO x 1) </p>\n<ol>\n<li>Slightly less efficiacy compared to standard short-course regimens </li>\n</ol>\n<p><strong><span class=\"drug\">Pivmecillinam</span></strong> (400 mg PO BID x 3-7 days) </p>\n<ol>\n<li>Only available in Europe</li>\n</ol>\n<p><strong><span class=\"drug\">Fluoroquinolones</span></strong> (3-day course of ofloxacin, ciprofloxacin, or levofloxacin) </p>\n<ol>\n<li>Avoid if possible to minimize selection of drug-resistant organisms</li>\n</ol>\n<p><strong>Beta-lactams</strong> (3-7 day course of <span class=\"drug\">amoxicillin</span>-clavulanate, <span class=\"drug\">cefdinir</span>, <span class=\"drug\">cefaclor</span>, <span class=\"drug\">cefpodoxime</span>-proxetil) </p>\n<ol>\n<li>Avoid if possible to minimize selection of drug-resistant organisms</li>\n<li> Inferior efficacy compared with standard regimens</li>\n<li><span class=\"drug\">Cephalexin</span> less well studied</li>\n</ol>\n<h2 id=\"acute-pyelonephritis\">Acute Pyelonephritis</h2>\n<p><strong>Urine analysis</strong> and <strong>urine culture</strong> should always be performed </p>\n<p><strong><span class=\"drug\">Ciprofloxacin</span></strong> (500 mg po BID x 7 days) +/- <strong><span class=\"drug\">ciprofloxacin</span></strong> 400 mg IV x 1 dose\nIf <strong>&gt; 10% resistance to fluoroquinolones</strong>, give 1-time IV dose:</p>\n<ul>\n<li><span class=\"drug\">Ceftriaxone</span> 1 gm IV, or </li>\n<li>An aminoglycoside </li>\n</ul>\n<p>If <strong>&lt; 10% resistance rate,</strong> alternative oral fluoroquinolone outpatient dosing options: </p>\n<ul>\n<li><span class=\"drug\">Ciprofloxacin</span> XR 1000 mg po daily x 7 days, or</li>\n<li><span class=\"drug\">Levofloxacin</span> 750 mg po daily x 5 days </li>\n</ul>\n<p><strong><span class=\"drug\">Trimethoprim</span>-sulfamethoxazole</strong> (1 tab DS PO BID x 14 days) </p>\n<ol>\n<li>If resistance rate unknown, give 1-time dose of <span class=\"drug\">ceftriaxone</span> 1 gm IV or  aminoglycoside first</li>\n</ol>\n<p><strong>  Beta-lactams</strong> (10-14 day course) </p>\n<ol>\n<li>Because of less efficacy, give 1-time dose of <span class=\"drug\">ceftriaxone</span> 1 gm IV or aminoglycoside first </li>\n</ol>\n<h2 id=\"references\">References</h2>\n<ul>\n<li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/10589881\">Gupta K et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the IDSA and the ESMID. Clin Infect Dis. 2011; 52(5).</a></li>\n</ul>\n"}}